Clinical Trial Update: Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating mirvetuximab soravtansine as first-line therapy in triple-negative breast cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Carcinoma

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 2 | Status: COMPLETED | Results posted: 2020-11-19